Showing 4761-4770 of 6803 results for "".
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators
- Dermwire's Inside Scoop on Hottest Expected AAD2016 Launcheshttps://practicaldermatology.com/news/dermwires-inside-scoop-on-hottest-expected-aad2016-launches/2458670/The American Academy of Dermatology (AAD)’s annual meeting is the place for skin care companies looking to launch the latest – and hopefully greatest --- innovations or iterations in skin care products and technologies. And the
- CMS: 2015 Hardship Exemption Does Not Impede EHR Incentiveshttps://practicaldermatology.com/news/cms-2015-hardship-exemption-does-not-impede-her-incentives/2458686/The
- Sweet Acne Cure: Kanuka Honey from New Zealand May Eradicate Acnehttps://practicaldermatology.com/news/sweet-acne-cure-kanuka-honey-from-new-zealand-may-eradicate-acne/2458693/Kanuka honey may help out the brakes on acne, new research suggests. In the study of Honevo®, developed by New Zealand pharmaceutical company HoneyLab, twice as many participants had an imp
- Hidradenitis Suppurativa Ups Risk of Adverse CV Eventshttps://practicaldermatology.com/news/hidradenitis-suppurativa-ups-risk-of-adverse-cv-events/2458696/Hidradenitis suppurativa (HS) may increase risk for adverse cardiovascular outcomes, a new study suggests. HS has been associated with cardiovascular risk factors, such as smoking and obesity, but the risk of cardiovascular disease in patients with HS was unknown. The new study
- Biosimilar News: Sandoz Acquires Biosimilar Infliximab In EEA, FDA Panel Urges Approval of Biosimilar Infliximab in UShttps://practicaldermatology.com/news/biosimilar-new-sandoz-acquires-biosimilar-infliximab-in-eea-fda-panel-urges-approval-of-biosimilar-infliximab-in-us/2458705/Two days after a US Food and Drug Administration (FDA) advisory panel voted to recommend approval of the biosimilar form of Remicade (Infliximab), Novartis’ Sandoz unit has acquired rights to develop and commercialize a biosimilar to Remicade® (i
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th
- Bristol-Myers Squibb's Opdivo + Yervoy Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Statushttps://practicaldermatology.com/news/bristol-myers-squibbs-opdivo-yervoy-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status/2458732/The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility